New Delhi | Jagran New Desk: In what could result in a major relief during the coronavirus pandemic, scientists in Netherlands have created a monoclonal antibody that can help in defeating the COVID-19 in the lab. The new research is a promising step in efforts to find the coronavirus vaccine and curb the spread of the deadly contagion.  

According to a report by Bloomberg, the monoclonal antibody has neutralized the cell in virus cultures. The clone antibody may help treat the COVID-19 and related disease in the future either alone or in a drug combination, according to a study published in in the journal Nature Communications on Monday. 

However, Berend-Jan Bosch of Utrecht University in the Netherlands and colleagues wrote in the journal that more extensive research is needed to find out that the findings are confirmed in a clinical setting and how specifically the monoclonal antibody is defeating the coronavirus.

According to the research, the antibody known as 47D11, attacks the spike protein which is responsible for the crown-like shape and lets it enter the human body. In the experiments done in Utrecht, the antibody didn’t just defeat the COVID-19 but also one of its cousin with similar spike protein, responsible for causing Severe Acute Respiratory Syndrome, or SARS.

Monoclonal antibodies are lab-created proteins that resemble naturally occurring versions the body raises to fight off bacteria and viruses. Highly potent, they target exactly one site on a virus. In this case, the scientists used genetically modified mice to produce different antibodies to the spike proteins of coronaviruses.

After a subsequent screening process, 47D11 emerged as showing neutralizing activity. Researchers then reformatted that antibody to create a fully human version, according to the paper.

"Monoclonal antibodies targeting vulnerable sites on viral surface proteins are increasingly recognized as a promising class of drugs against infectious diseases and have shown therapeutic efficacy for a number of viruses," Bosch and colleagues wrote as reported by Bloomberg.

Posted By: Talib Khan